Could a pill keep endometrial cancer at bay? new study tests rucaparib
NCT ID NCT03617679
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug rucaparib can help keep metastatic or recurrent endometrial cancer from growing. 79 women who had already received chemotherapy took either rucaparib or a placebo pill twice daily. The goal was to see if rucaparib could delay cancer progression and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rucaparib (a PARP inhibitor drug taken as a pill)
What this could lead to
If successful, rucaparib could offer a new maintenance option to delay cancer progression in people with advanced endometrial cancer.
What could go wrong
This is a Phase 2 trial with only 79 participants, so results may not be definitive. Rucaparib can cause side effects like fatigue, nausea, and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States